SYRE
VENTE TOTALE: 35 000 titres (~3 227 300,00 $ US)
- Insiders
- Turtle Cameron, Albers Jeffrey W.
- Total bought
- —
- Total sold
- $3,227,300
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-07
SYRE presents a deeply concerning profile: despite strong liquidity (score 85), the company generates zero revenue with persistent negative margins and no visible path to profitability, making cash reserves a countdown…
The first sentence of the analysis written for SYRE on 2026-09-07 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | -14510.6% | -3604.6% | -350.4% | |
| Ebitda Margin | 0.0% | 0.0% | -14401.8% | -3520.3% | -342.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -27348.0% | -3640.2% | -350.3% | |
| Pretax Profit Margin | 0.0% | 0.0% | -38241.1% | -3604.6% | -350.4% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | -38238.1% | -3598.8% | -351.1% | |
| Net Profit Margin | 0.0% | 0.0% | -38238.1% | -3598.8% | -351.1% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | -10709.1% | -3598.8% | -351.1% | |
| Current Ratio | 13.253 | 11.256 | 10.680 | 4.248 | 4.909 | |
| Quick Ratio | 13.253 | 11.256 | 10.680 | 4.248 | 4.909 | |
| Solvency Ratio | -2.322 | -2.294 | -2.140 | -3.928 | -2.472 | |
| Cash Ratio | 1.461 | 1.654 | 5.907 | 2.379 | 0.752 | |
| Price To Earnings Ratio | -16.545 | -7.321 | -0.466 | -0.453 | -4.746 | |
| Price To Earnings Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Forward Price To Earnings Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Price To Earnings Diluted Ratio | -16.545 | -7.321 | -0.466 | -0.453 | -4.746 | |
| Price To Earnings Diluted Growth Ratio | 0.438 | 0.079 | -0.005 | 0.708 | 0.140 | |
| Price To Book Ratio | 2.934 | 2.114 | 0.807 | 0.754 | 3.720 | |
| Price To Sales Ratio | 0.000 | 0.000 | 167.522 | 16.284 | 16.665 | |
| Price To Free Cash Flow Ratio | -12.399 | -6.955 | -1.486 | -0.473 | -5.752 | |
| Price To Operating Cash Flow Ratio | -12.399 | -6.955 | -1.486 | -0.473 | -5.814 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.065 | 0.046 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.092 | 0.060 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.084 | 0.057 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.087 | 1.175 | 1.858 | 1.414 | 1.310 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.005 | 0.037 | 0.177 | |
| Operating Cash Flow Ratio | -2.884 | -2.912 | -3.124 | -5.468 | -2.667 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | -112.765 | -34.411 | -2.867 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.011 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -17.313 | -10.616 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | -2,109.053 | -93.745 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | -2,109.053 | -93.745 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -9.605 | -4.834 | 0.317 | -0.094 | -4.716 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-60.0% |
| Ebit Margin | 0.0% | 0.0% | ▲3693.1% |
| Ebitda Margin | 0.0% | 0.0% | ▲3652.8% |
| Operating Profit Margin | 0.0% | 0.0% | ▲6267.7% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲8439.2% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲8437.6% |
| Net Profit Margin | 0.0% | 0.0% | ▲8437.6% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲2931.8% |
| Current Ratio | 13.254 | ▲1.998 | ▲4.384 |
| Quick Ratio | 13.254 | ▲1.998 | ▲4.384 |
| Solvency Ratio | -2.322 | ▼-0.028 | ▲0.309 |
| Cash Ratio | 1.461 | ▼-0.193 | ▼-0.970 |
| Price To Earnings Ratio | -16.546 | ▼-9.225 | ▼-10.639 |
| Price To Earnings Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Forward Price To Earnings Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Price To Earnings Diluted Ratio | -16.546 | ▼-9.225 | ▼-10.639 |
| Price To Earnings Diluted Growth Ratio | 0.439 | ▲0.360 | ▲0.167 |
| Price To Book Ratio | 2.934 | ▲0.820 | ▲0.868 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-40.094 |
| Price To Free Cash Flow Ratio | -12.399 | ▼-5.444 | ▼-6.986 |
| Price To Operating Cash Flow Ratio | -12.399 | ▼-5.444 | ▼-6.973 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.022 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.030 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.028 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.087 | ▼-0.088 | ▼-0.281 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.044 |
| Operating Cash Flow Ratio | -2.884 | ▲0.028 | ▲0.527 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲30.009 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.586 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲440.560 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲440.560 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -9.605 | ▼-4.770 | ▼-5.818 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.10B | $1.09B | $148.4M | $37.9M | $312.3M | |
| Enterprise value | $2.01B | $1.01B | -$40.5M | $7.7M | $302.2M | |
| EV / Sales | 0.00x | 0.00x | -45.67x | 3.30x | 16.13x | |
| EV / Op. cash flow | -11.89x | -6.39x | 0.41x | -0.10x | -5.63x | |
| EV / Free cash flow | -11.89x | -6.39x | 0.41x | -0.10x | -5.57x | |
| EV / EBITDA | -9.61x | -4.83x | 0.32x | -0.09x | -4.72x | |
| Net debt / EBITDA | 0.41x | 0.43x | 1.48x | 0.37x | 0.16x | |
| Current ratio | 13.25x | 11.26x | 10.68x | 4.25x | 4.91x | |
| Income quality | 1.09x | 0.76x | 0.29x | 0.96x | 0.82x | |
| Graham net-net | $11 | $11 | $26 | $10 | $26 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 99.8% | 100.2% | |
| Interest burden | 70.7% | 100.0% | 263.5% | 100.0% | 100.0% | |
| Working capital | $719.1M | $554.4M | $309.6M | $47.6M | $78.7M | |
| Invested capital | $719.1M | $554.4M | $309.6M | $54.3M | $87.1M | |
| Return on assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% | |
| Operating ROA | -30.2% | -43.9% | -117.3% | -93.6% | -48.4% | |
| Return on tangible assets | -20.0% | -34.2% | -99.1% | -117.8% | -59.9% | |
| Return on equity | -21.7% | -40.2% | -184.1% | -166.6% | -78.4% | |
| Return on invested capital | -29.1% | -37.6% | -78.2% | -148.2% | -72.8% | |
| Return on capital employed | -29.1% | -37.6% | -78.2% | -150.1% | -73.1% | |
| Earnings yield | -7.4% | -19.0% | -228.3% | -221.0% | -21.1% | |
| Free cash flow yield | -8.1% | -14.4% | -67.3% | -211.4% | -17.4% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | -0.0% | -1.1% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 2.4% | 36.4% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 1.6% | 3.1% | |
| SG&A / Sales | 0.0% | 0.0% | 4508.6% | 1225.0% | 145.8% | |
| R&D / Sales | 0.0% | 0.0% | 10102.0% | 2515.2% | 304.5% | |
| Stock comp / Sales | 0.0% | 0.0% | 2897.9% | 305.3% | 42.9% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 59d | 16d | |
| Days payables outstanding | 19d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 59d | 16d | |
| Cash conversion cycle | -19d | 0d | 0d | 59d | 16d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+91.7%EV / Sales n/aEV / EBITDA ▼-98.7%EV / Op. cash flow ▼-5.505Earnings yield ▲+0.116
Profitability
Return on equity ▲+0.185Return on assets ▲+0.142Return on invested capital ▲+0.085Return on capital employed ▲+0.085Operating ROA ▲+0.137Income quality ▲+0.334Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.998Net debt / EBITDA ▼-0.021Working capital ▲+164682000.000Invested capital ▲+164682000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+572.0%EV / Sales ▼-100.0%EV / EBITDA ▼-103.7%EV / Op. cash flow ▼-6.266Earnings yield ▲+0.137
Profitability
Return on equity ▲+0.567Return on assets ▲+0.399Return on invested capital ▲+0.436Return on capital employed ▲+0.440Operating ROA ▲+0.181Income quality ▲+0.274Tax burden ▼-0.002
Efficiency
Days sales outstanding ▼-15.875Days payables outstanding n/aOperating cycle ▼-15.875Cash conversion cycle ▼-34.808Capex / Sales ▼-0.031R&D / Sales ▼-3.045
Balance-sheet strength
Current ratio ▲+8.344Net debt / EBITDA ▲+0.252Working capital ▲+640349000.000Invested capital ▲+631994000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-04 Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre''s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 2,106 shares of common stock of Spyre and 745 restricted stock units (“RSUs”) to one non-executive employee as an equity inducement award under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on September 1, 2026 and were material to the employee''s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-03 Spyre Therapeutics to Participate in Upcoming September Investor Conferences WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences: Event : Citi 2026 BioPharma Back to School Conference – New York Date: Wednesday, September 9, 2026 Fireside Time: 10:00 am ET Event: Wells Fargo 21st Annual Healthcare Conference – Boston Date: Thursday, September 10, 2026 Fireside Time: 8:00 am ET Event: Stifel 2026 Virtual Immunology and Inflammation Forum Date: Wednesday, September 23, 2026 Fireside Time: 8:30 am ET Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
- 2026-09-03 Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? Spyre Therapeutics (SYRE) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-26 SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis Spyre''s SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
- 2026-08-26 Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.
- 2026-08-25 Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
- 2026-08-24 Can Spyre''s SPY772 HS Study Broaden Its Growth Story Beyond Core IBD? SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
- 2026-08-24 Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk? Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
- 2026-08-24 SYRE Rallies 44.9% in 3 Months. Can Clinical Catalysts Sustain It? Spyre''s 2026 clinical catalysts and positive ulcerative colitis data fuel momentum, but its lofty valuation raises the stakes for upcoming readouts.
- 2026-08-07 Spyre Therapeutics Announces Grants of Inducement Awards WALTHAM, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre''s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 19,436 shares of common stock of Spyre and 6,186 restricted stock units (“RSUs”) to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on August 3, 2026 and were material to each employee''s acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).